The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

Publications

Bugés C, Carcereny E, Moran T, Cardona AF, Reguart N, Capdevila L, Cros S, Rosell R

Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.

Clinical lung cancer 2015 Mar;16;e1-3 — 2015 Mar — e1-3

Ji Y, Zhang Z, Nie K, Lan K, Geng C, Liu S, Zhang L, Zhang Z, Sun L, Zou X

Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.

Chinese medical journal 2014;127;1600 — 2014 — 1600

Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jan 01;31;e15-7 — 2013 Jan 01 — e15-7